AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (2.4 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Publishing Language: Chinese

Establishment of rat model of sarcopenia by ovariectomy and estrogen replacement therapy

Yubin HUANGLi LINGZheng'ai XIONG( )
Department of Gynecology and Obstetrics, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China
Show Author Information

Abstract

Objective

To establish a rat model of postmenopausal sarcopenia and explore the therapeutic effect of estrogen supplementary therapy on the disease.

Methods

① Forty-four 12-week-old female SD rats(220±20 g)were randomly divided into sham group and ovariectomized(OVX)group by stratified random sampling based on body weight, with 22 rats in each group. The rats of the OVX group were given bilateral ovariectomy, while those of the SHAM group underwent sham surgery. The body weight was monitored, and the grip strength of the forelimb was measured using an electronic grip strength meter. In 12 weeks after surgery, the body composition was analyzed by X-ray absorptiometry(DXA)to identify the model establishment by relative lean mass. Ten rats in each group were sacrificed to harvest the gastrocnemius, and then sarcopenia index(SI)was calculated as the ratio of gastrocnemius mass to body weight. HE staining and transmission electron microscopy were applied respectively to observe the cross-sectional area of the muscle fibers and the structure of myofibrils were determined. ② The remaining rats were further divided into SHAM group, SHAM+O group, OVX group and OVX+E2 group, with 6 rats in each group. 17β-estradiol was injected subcutaneously in OVX+E2 group, while control solvent(10% DMSO+90%sesame oil)was injected subcutaneously in SHAM+O group. The grip strength and body composition were measured and body composition was analyzed. ELISA was used to measure the serum levels of E2 and FSH, HE staining was employed to observe the cross-sectional area of gastrocnemius muscle fibers, electron microscopy was conducted to observe the ultrastructure of myofibrils, and immunofluorescence staining was applied to analyze the expression of Bax and Bcl-2.

Results

①After 12 weeks of modeling, the rats in the OVX group had significant lower relative lean mass(P<0.001), indicating the successful establishment of sarcopenia model, and had obviously increased body weight(P<0.001)and body fat rate(P<0.001), but decreased relative grip(P<0.001), SI value, average cross sectional area of the muscle fibers(P<0.01), and mitochondrial density(P=0.012). ② Estrogen supplementary therapy resulted in similar body weight, body fat rate, grip strength, relative lean mass, SI value, average cross sectional area of the muscle fibers, and mitochondrial density in the rats in OVX+E2 group when compared with those of SHAM group. Immunofluorescence assay revealed that OVX group had a notably lower Bcl-2/Bax ratio than the SHAM and OVX+E2 groups(P<0.01).

Conclusion

A rat model of postmenopausal sarcopenia is successfully established. Estrogen supplementary therapy can significantly improve the muscle mass loss in ovariectomized rats, which may be associated with estrogen inhibiting myocyte apoptosis.

CLC number: R589.305; R711.51; R977.12 Document code: A

References

[1]
JIANG S, KANG L, LIU X H. Interpretation of Asian Working Group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. Chin J Geriatr, 2020, 394): 373-376. DOI: 10.3760/cma.j.issn.0254-9026.2020.04.002.
[2]
CHEN L K, WOO J, ASSANTACHAI P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 213): 300-307. e2. DOI: 10.1016/j.jamda.2019.12.012.
[3]
LI C W, YU K. Research progress on pathogenesis of muscular dystrophy and its guiding significance for clinicaldiagnosis[J]. Sci Sin Vitae, 2021, 518): 1170-1179. DOI: 10.1360/SSV-2021-0188.
[4]
GAO J X, QIU Y D, HOU Y F, et al. Influencing factors for the decline of limb muscle strength and the association with all-cause mortality: evidence from a nationwide population-based cohort study[J]. Aging Clin Exp Res, 2022, 342): 399-407. DOI: 10.1007/s40520-021-01940-w.
[5]
XIA X M, WANG H, JI Y B, et al. A meta-analysis of the influencing factors of sarcopenia among the elderly in Chinese community[J]. Mod Prev Med, 2022, 495): 946-950, 960. DOI: 10.16821/j.cnki.hsjx.2021.04.010.
[6]
CHANG J Y, HUANG B, JIANG T J. Sarcopenia in postmenopausal women[J]. Chin J Osteoporos, 2019, 259): 1345-1350. DOI: 10.3969/j.issn.1006-7108.2019.09.028.
[7]
HANSEN M. Female hormones: do they influence muscle and tendon protein metabolism?[J]. Proc Nutr Soc, 2018, 771): 32-41. DOI: 10.1017/S0029665117001951.
[8]
ENNS D L, TIIDUS P M. The influence of estrogen on skeletal muscle[J]. Sports Med, 2010, 401): 41-58. DOI: 10.2165/11319760-000000000-00000.
[9]
GERACI A, CALVANI R, FERRI E, et al. Sarcopenia and menopause: the role of estradiol[J]. Front Endocrinol(Lausanne), 2021, 12: 682012. DOI: 10.3389/fendo.2021.682012.
[10]
KENNY A M, DAWSON L, KLEPPINGER A, et al. Prevalence of sarcopenia and predictors of skeletal muscle mass in nonobese women who are long-term users of estrogen-replacement therapy[J]. J Gerontol A Biol Sci Med Sci, 2003, 585): M436-M440. DOI: 10.1093/gerona/58.5.m436.
[11]
PINGEL J, LANGBERG H, SKOVGÅRD D, et al. Effects of transdermal estrogen on collagen turnover at rest and in response to exercise in postmenopausal women[J]. J Appl Physiol(1985), 2012, 1137): 1040-1047. DOI: 10.1152/japplphysiol.01463.2011.
[12]
RONKAINEN P H, PÖLLÄNEN E, ALÉN M, et al. Global gene expression profiles in skeletal muscle of monozygotic female twins discordant for hormone replacement therapy[J]. Aging Cell, 2010, 96): 1098-1110. DOI: 10.1111/j.1474-9726.2010.00636.x.
[13]
ZHOU X N, YUAN S, ZHAO Q, et al. Research progress in modeling methods of sarcopenia[J]. Chin J Osteoporos, 2022, 289): 1365-1368. DOI: 10.3969/j.issn.1006-7108.2022.09.022.
[14]
YANG X, WANG Y B, YU J. Research progress of animal models ofsarcopenia[J]. J Brain Nerv Dis, 2022, 305): 328-330, F0003, 324. DOI: 10.1002/jcsm.12460.
[15]
EDSTRÖM E. Sarcopenia[M]. Stockholm: Karolinska Institutet, 2005: 12-24.
[16]
SHEN L X, YUAN B Y, WANG L, et al. 17β-estradiol attenuates hypoxia-induced pulmonary vascular remodeling via downregulating miRNA-21 signaling pathway[J]. Chin Circ J, 2018, 3311): 1118-1123. DOI: 10.3969/j.issn.1000-3614.2018.11.017.
[17]
XIN W, QI S S, ZENG H T. Effect of estrogen on uterine tissue morphology in ovariectomized osteoporosis rats[J]. Heilongjiang Animal Sci Vet Med, 20168): 220-222, 299.
[18]
SZEGEZDI E, MACDONALD D C, NÍ CHONGHAILE T, et al. Bcl-2 family on guard at the ER[J]. Am J Physiol Cell Physiol, 2009, 2965): C941-C953. DOI: 10.1152/ajpcell.00612.2008.
[19]
CAPLLONCH-AMER G, SBERT-ROIG M, GALMÉS-PASCUAL B M, et al. Estradiol stimulates mitochondrial biogenesis and adiponectin expression in skeletal muscle[J]. J Endocrinol, 2014, 2213): 391-403. DOI: 10.1530/JOE-14-0008.
[20]
HUANG C H, LIU J, XU D M, et al. New research advances in muscle mass determination methods[J]. Chin J Osteoporos, 2022, 289): 1385-1389. DOI: 10.3969/j.issn.1006-7108.2022.09.026.
[21]
CRUZ-JENTOFT A J, BAHAT G, BAUER J, et al. Sarcopenia: revised European consensus on definition and diagnosis[J]. Age Ageing, 2019, 484): 601. DOI: 10.1093/ageing/afz046.
[22]
SAYED R K, DE LEONARDIS E C, GUERRERO-MARTÍNEZ J A, et al. Identification of morphological markers of sarcopenia at early stage of aging in skeletal muscle of mice[J]. Exp Gerontol, 2016, 83: 22-30. DOI: 10.1016/j.exger.2016.07.007.
[23]
LEDUC-GAUDET J P, HUSSAIN S N A, BARREIRO E, et al. Mitochondrial dynamics and mitophagy in skeletal muscle health and aging[J]. Int J Mol Sci, 2021, 2215): 8179. DOI: 10.3390/ijms22158179.
[24]
RIBAS V, DREW B G, ZHOU Z Q, et al. Skeletal muscle action of estrogen receptor α is critical for the maintenance of mitochondrial function and metabolic homeostasis in females[J]. Sci Transl Med, 2016, 8334): 334ra54. DOI: 10.1126/scitranslmed.aad3815.
[25]
VASCONSUELO A, PRONSATO L, RONDA A C, et al. Role of 17β-estradiol and testosterone in apoptosis[J]. Steroids, 2011, 7612): 1223-1231. DOI: 10.1016/j.steroids.2011.08.001.
[26]
COLLA A L, VASCONSUELO A, MILANESI L, et al. 17β-estradiol protects skeletal myoblasts from apoptosis through p53, bcl-2, and FoxO families[J]. J Cell Biochem, 2017, 1181): 104-115. DOI: 10.1002/jcb.25616.
[27]
CHENG J N, ZHANG L, GENG X, et al. Research progress on the regulatory mechanism of Bcl-2 family on the exercise adaptability of skeletal muscle cells[J]. Chin J Sports Med, 2019, 381): 74-80. DOI: 10.3969/j.issn.1000-6710.2019.01.012.
Journal of Army Medical University
Pages 1937-1946
Cite this article:
HUANG Y, LING L, XIONG Z. Establishment of rat model of sarcopenia by ovariectomy and estrogen replacement therapy. Journal of Army Medical University, 2023, 45(18): 1937-1946. https://doi.org/10.16016/j.2097-0927.202303072

7

Views

0

Downloads

0

Crossref

0

Scopus

0

CSCD

Altmetrics

Received: 14 March 2023
Revised: 30 May 2023
Published: 30 September 2023
© 2023 Journal of Army Medical University
Return